Huadong Pharmaceutical and Alibaba Health have reached a cooperation, and the first domestically produced Liraglutide has been launched for the first time

On May 19th, it was reported that Liraglutide Injection (Chinese product name: Liraglutide), a wholly-owned subsidiary of Huadong Pharmaceutical, has been launched online at Alibaba Health Pharmacy. Searching for "Lilalutide" on Taobao, we found that we can directly access the relevant prescription and consultation pages, which means that domestic patients with type 2 diabetes (T2DM) have more convenient new treatment options

On May 19th, it was reported that Liraglutide Injection (Chinese product name: Liraglutide), a wholly-owned subsidiary of Huadong Pharmaceutical, has been launched online at Alibaba Health Pharmacy. Searching for "Lilalutide" on Taobao, we found that we can directly access the relevant prescription and consultation pages, which means that domestic patients with type 2 diabetes (T2DM) have more convenient new treatment options.

It is reported that liraglutide is a GLP-1 receptor agonist that can increase intracellular cAMP, promote insulin release, lower blood sugar, and reduce glucagon secretion and delayed gastric emptying. For a long time, most of the formulations used in China have relied on imports, resulting in high treatment costs. Rilaglutide biosimilar, which was approved by the National Drug Administration (NMPA) for marketing on March 28, 2023, is applicable to adult diabetes patients with type 2 diabetes to control blood sugar and to reduce the risk of major cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in adult diabetes patients with cardiovascular disease.

From the perspective of East China Medicine, Liluping is the first domestic Lilalutide injection listed on the market, which will further enrich the company's product pipeline in the field of diabetes, and also bring new drug choices to domestic patients. The application for marketing license for its weight loss indications was also accepted in July 2022 and is expected to be approved within the year.

Mr. Zhang Jianfei, Deputy General Manager of East China Pharmaceutical Co., Ltd., stated that China, the United States, and East China have been deeply involved in the fields of kidney disease, autoimmune, endocrine, and cardiovascular diseases for many years, providing high-quality and effective treatment plans for a large number of patients. I hope to take advantage of the launch of Liluping as an opportunity to continuously expand the depth and breadth of cooperation with Alibaba Health, promote mutual complementarity of advantages, and enable better products and services to benefit more patients.

It is reported that Alibaba Health and East China Medicine will further collaborate in the field of endocrine disease treatment, jointly exploring medical and health services such as science popularization and patient education, online diagnosis and treatment, and digital patient management. (One Orange)